Patients treated with a tumor necrosis factor-α inhibitor are more likely to develop extrapulmonary tuberculosis

Korean Journal of Internal Medicine

Volumn 28, Issue 2, 2013, Pages 159-161

  Lee, Sang Oh ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; BIOPSY; CROHN DISEASE; DRUG APPROVAL; DRUG EFFICACY; EDITORIAL; ENTERITIS; EXTRAPULMONARY TUBERCULOSIS; HUMAN; IMMUNE RESPONSE; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY GRAFT; KOREA; LIVER GRAFT; PREVALENCE; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; TISSUE BIOPSY; TREATMENT RESPONSE; TUBERCULIN TEST; ANTAGONISTS AND INHIBITORS; FEMALE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MALE; TUBERCULOSIS;

FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MALE; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875510933     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2013.28.2.159     Document Type: Editorial

References (10)

1. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-1206.
2. Maini R, St Clair EW, Breedveld F, et al. Inf liximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial: ATTRACT Study Group. Lancet 1999;354:1932-1939.
3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with inf liximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
4. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69:1847-1855.
5. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-711.
6. Chung KB, Lee EY, Im JP, Han SK, Yim JJ. Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor. Korean J Intern Med 2013;28:174-179.
7. Canet E, Dantal J, Blancho G, Hourmant M, Coupel S. Tuberculosis following kidney transplantation: clinical features and outcome: a French multicentre experience in the last 20 years. Nephrol Dial Transplant 2011;26:3773-3778.
8. Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009;15:894-906.
9. Yun JW, Lim SY, Suh GY, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci 2007;22:779-783.
10. Hur JA, Seo SH, Park SH, Cho CS, Kim HY. Discrepancy between the tuberculin skin test and the T-SPOT.TB for detecting latent Mycobacterium tuberculosis infection in patients with rheumatoid arthritis. J Korean Rheum Assoc 2006;13:285-290.